The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness
The American Diabetes Association (ADA) and Xeris Pharmaceuticals have announced a multi-year strategic partnership to promote awareness about glucagon prescriptions for diabetes patients. The collaboration focuses on emphasizing that all individuals with diabetes on blood glucose-lowering medications should have glucagon, preferably in ready-to-use form.
Key statistics highlight that up to 46% of type 1 diabetes patients and 21% of type 2 diabetes patients using insulin experience at least one severe hypoglycemia event annually. These events result in over 202,000 emergency department visits yearly, with 25% requiring hospitalization.
The partnership aims to develop educational materials and training resources for healthcare professionals and diabetes patients, alongside launching a national awareness campaign. The initiative aligns with ADA's updated Standards of Care in Diabetes—2025, addressing the critical need for proper glucagon prescription rates and emergency preparedness for those at risk of severe hypoglycemia.
L'Associazione Americana di Diabete (ADA) e Xeris Pharmaceuticals hanno annunciato una partnership strategica pluriennale per promuovere la consapevolezza riguardo le prescrizioni di glucagone per i pazienti diabetici. La collaborazione si concentra sull'importanza che tutte le persone con diabete che utilizzano farmaci per abbassare la glicemia abbiano accesso al glucagone, preferibilmente in forma pronte all'uso.
Statistiche chiave evidenziano che fino al 46% dei pazienti con diabete di tipo 1 e il 21% dei pazienti con diabete di tipo 2 che usano insulina sperimentano almeno un episodio grave di ipoglicemia all'anno. Questi eventi comportano oltre 202.000 visite al pronto soccorso ogni anno, con il 25% che richiede ospedalizzazione.
La partnership mira a sviluppare materiali educativi e risorse di formazione per i professionisti sanitari e i pazienti diabetici, oltre a lanciare una campagna nazionale di sensibilizzazione. L'iniziativa si allinea con gli standard aggiornati di cura del diabete dell'ADA - 2025, affrontando la necessità critica di tassi adeguati di prescrizione di glucagone e preparazione alle emergenze per coloro a rischio di grave ipoglicemia.
La Asociación Americana de Diabetes (ADA) y Xeris Pharmaceuticals han anunciado una asociación estratégica a largo plazo para promover la conciencia sobre las recetas de glucagón para pacientes con diabetes. La colaboración se centra en enfatizar que todas las personas con diabetes que toman medicamentos para reducir la glucosa en sangre deben tener glucagón, preferiblemente en forma lista para usar.
Las estadísticas clave destacan que hasta el 46% de los pacientes con diabetes tipo 1 y el 21% de los pacientes con diabetes tipo 2 que usan insulina experimentan al menos un evento grave de hipoglucemia anualmente. Estos eventos resultan en más de 202,000 visitas a urgencias cada año, con un 25% que requiere hospitalización.
La asociación tiene como objetivo desarrollar materiales educativos y recursos de capacitación para profesionales de la salud y pacientes diabéticos, además de lanzar una campaña nacional de concientización. La iniciativa se alinea con los estándares de atención actualizados de la ADA para 2025, abordando la necesidad crítica de tasas adecuadas de prescripción de glucagón y preparación ante emergencias para aquellos en riesgo de hipoglucemia severa.
미국 당뇨병 협회 (ADA)와 Xeris Pharmaceuticals는 당뇨병 환자를 위한 글루카곤 처방에 대한 인식을 증진하기 위해 다년간의 전략적 파트너십을 발표했습니다. 이번 협력은 혈당 강하제를 복용하는 모든 당뇨병 환자는 가능한 한 사용 준비가 된 형태로 글루카곤을 가져야 한다는 점을 강조하는 데 초점을 맞추고 있습니다.
주요 통계에 따르면, 1형 당뇨병 환자의 46%와 2형 당뇨병 환자의 21%가 인슐린을 사용하는 환자들은 매년 최소한 한 번 심각한 저혈당 사건을 경험합니다. 이러한 사건들은 매년 202,000건 이상의 응급실 방문을 초래하며, 그 중 25%는 입원이 필요합니다.
이번 파트너십은 의료 전문가와 당뇨병 환자를 위한 교육 자료 및 훈련 리소스를 개발하고, 전국적인 인식 캠페인을 시작하는 것을 목표로 합니다. 이 이니셔티브는 ADA의 2025년 업데이트된 당뇨병 치료 기준과 일치하며, 심각한 저혈당의 위험이 있는 환자에 대한 적절한 글루카곤 처방률과 응급 대응 필요성을 해결합니다.
L'Association Américaine du Diabète (ADA) et Xeris Pharmaceuticals ont annoncé un partenariat stratégique pluriannuel pour promouvoir la sensibilisation à la prescription de glucagon pour les patients diabétiques. La collaboration se concentre sur le fait que toutes les personnes diabétiques sous traitements pour abaisser la glycémie doivent avoir du glucagon, de préférence sous forme prête à l'emploi.
Les statistiques clés soulignent qu'environ 46% des patients diabétiques de type 1 et 21% des patients diabétiques de type 2 utilisant de l'insuline éprouvent au moins un événement grave d'hypoglycémie chaque année. Ces événements entraînent plus de 202 000 visites aux urgences chaque année, dont 25 % nécessitent une hospitalisation.
Le partenariat vise à développer des supports éducatifs et des ressources de formation pour les professionnels de santé et les patients diabétiques, tout en lançant une campagne nationale de sensibilisation. L'initiative s'aligne sur les nouvelles normes de soins en diabète de l'ADA - 2025, répondant au besoin crucial de taux appropriés de prescription de glucagon et de préparation aux urgences pour ceux à risque d'hypoglycémie sévère.
Die American Diabetes Association (ADA) und Xeris Pharmaceuticals haben eine strategische Partnerschaft über mehrere Jahre angekündigt, um das Bewusstsein für die Verschreibung von Glukagon bei Diabetespatienten zu fördern. Die Zusammenarbeit konzentriert sich darauf, dass alle Menschen mit Diabetes, die blutzuckersenkende Medikamente einnehmen, Glukagon haben sollten, vorzugsweise in gebrauchsfertiger Form.
Wichtigste Statistiken zeigen, dass bis zu 46% der Patienten mit Typ-1-Diabetes und 21% der Patienten mit Typ-2-Diabetes, die Insulin verwenden, jährlich mindestens ein schweres Hypoglykämieereignis erfahren. Diese Ereignisse führen jährlich zu über 202.000 Notaufnahmebesuchen, wobei 25% eine Krankenhausaufnahme erfordern.
Die Partnerschaft zielt darauf ab, Schulungsmaterialien und Ressourcen für Fachkräfte im Gesundheitswesen und Diabetespatienten zu entwickeln und gleichzeitig eine nationale Sensibilisierungskampagne zu starten. Die Initiative steht im Einklang mit den aktualisierten Standards der diabetesmedizinischen Versorgung der ADA - 2025, die den kritischen Bedarf an angemessenen Glukagonverschreibungsraten und Notfallvorbereitungen für diejenigen anspricht, die gefährdet sind, eine schwere Hypoglykämie zu erleiden.
- None.
- None.
Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation
"Severe hypoglycemia is life-threatening, and people with diabetes on blood glucose-lowering medication are at risk for hypoglycemia. Thus, we must act with urgency to educate people about the importance of having a treatment plan in place that includes having glucagon on hand," said Charles "Chuck"
It is estimated that up to
The ADA, with support from Xeris, seeks to rectify the low rates of appropriate glucagon prescriptions by developing education materials and training resources for health care professionals and people living with diabetes, as well as through a national awareness campaign to educate people on who is at risk for severe hypoglycemia and should have glucagon, preferably ready-to-use, as a safety net.
"Severe hypoglycemia is associated with up to a three-time increased risk of death in people with diabetes.4,5,6 Xeris is proud to collaborate with the ADA to urge adoption of their strengthened clinical practice recommendations around the treatment of severe hypoglycemia," said John Shannon, Xeris' CEO. "The stakes are too high for so many patients at risk to be without a safety net. Our mutual commitment is to fight for all patients living with diabetes and ensure that they can face severe low blood glucose emergencies with confidence by always having a ready-to-use glucagon on hand."
To learn more about the importance of severe hypoglycemia, readiness and treatment options, visit diabetes.org/severehypo.
About the American Diabetes Association
The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to end diabetes and helping people thrive. For 84 years, the ADA has driven discovery and research to prevent, manage, treat, and ultimately cure diabetes. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), and Instagram (@AmDiabetesAssn). To learn more about how we are advocating for everyone affected by diabetes, visit us on X (@AmDiabetesAssn).
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing's syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism as well as multiple early-stage programs leveraging Xeris' technology platforms, XeriSol® and XeriJect®, for its partners.
Xeris Biopharma Holdings is headquartered in
- American Diabetes Association Professional Practice Committee; 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025. Diabetes Care 1 January 2025; 48 (Supplement_1): S128–S145. https://doi.org/10.2337/dc25-S006
- Stuckey HL, Desai U, King SB, et al. The experience of a severe hypoglycaemic event from the perspective of people with diabetes and their caregivers: "What am I going to do?". Diabet Med. 2022;39(4):e14745. doi:10.1111/dme.14745
- Centers for Disease Control and Prevention. National Diabetes Statistics Report. Accessed January 8, 2025. https://www.cdc.gov/diabetes/php/data-research/index.html
- Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384-1395. doi:10.2337/dc12-2480
- McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35(9):1897-1901. doi:10.2337/dc11-2054
- Zoungas S, Patel A, Chalmers J, et al. Severe Hypoglycemia and Risks of Vascular Events and Death. N Engl J Med. 2010;363(15):1410-1418. doi: 10.1056/NEJMoa1003795.
Contact: Virginia Cramer, (703) 253-4927
press@diabetes.org
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-american-diabetes-association-and-xeris-pharmaceuticals-announce-national-collaboration-to-provide-life-saving-hypoglycemia-education-and-awareness-302355703.html
SOURCE American Diabetes Association
FAQ
What are the key objectives of the ADA and Xeris Pharmaceuticals collaboration announced in January 2025?
How many diabetes patients experience severe hypoglycemia events annually according to the 2025 announcement?
What is the annual impact of hypoglycemia on emergency department visits?
How does severe hypoglycemia affect mortality rates in diabetes patients?
What specific recommendations does the ADA's 2025 Standards of Care make regarding glucagon?
